Matthew Kurian: Gedatolisib in PIK3CA-Mutated HR+/HER2− Metastatic Breast Cancer

Coverage, in order

1. 7h ago
   
   first OncoDaily obscure study

   Matthew Kurian: Gedatolisib in PIK3CA-Mutated HR+/HER2− Metastatic Breast Cancer

   Matthew Kurian, Physician at St. Elizabeth Healthcare, shared on LinkedIn: “Another major development in HR+/HER2− metastatic breast cancer! The FDA has accepted the sNDA for gedatolisib in PIK3CA-mutated disease on

2. 7h ago
   
   OncoDaily obscure study

   Matthew Kurian: Gedatolisib in PIK3CA-Mutated HR+/HER2− Metastatic Breast Cancer

   Matthew Kurian, Physician at St. Elizabeth Healthcare, shared on LinkedIn: “Another major development in HR+/HER2− metastatic breast cancer! The FDA has accepted the sNDA for gedatolisib in PIK3CA-mutated disease on

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.